You are here

A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Langenthal, BE, Switzerland
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hyperlipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see
appendix B) at screening

- LDL-C

- Triglyceride level

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy
(LLT) at screening.

NCT00136942
Pfizer
Completed
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now